Ventyx Biosciences, Inc. has entered into a Securities Purchase Agreement to sell 70,601 shares of Series A Non-Voting Convertible Preferred Stock to Aventis Inc. for approximately $27 million, convertible into Common Stock at a price of $3.8243 per...